Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 9165267, 7 pages
http://dx.doi.org/10.1155/2016/9165267
Clinical Study

Clinical Observation of Employment of Umbilical Cord Derived Mesenchymal Stem Cell for Juvenile Idiopathic Arthritis Therapy

1Cell Therapy Center, 323 Hospital of People’s Liberation Army, Xi’an 710054, China
2Zhongyuan Union Cell & Gene Engineering Corporation Company, Tianjin 300304, China
3Alliancells Institute of Stem Cells and Translational Regenerative Medicine & Alliancells Bioscience Co., Ltd., Tianjin 300381, China
4Harold Hamm Oklahoma Diabetes Center and Section of Endocrinology and Diabetes in the Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Received 28 April 2015; Revised 31 July 2015; Accepted 6 August 2015

Academic Editor: Kathryn McFadden

Copyright © 2016 Liming Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Ringold, A. Burke, and R. M. Glass, “Juvenile idiopathic arthritis,” The Journal of the American Medical Association, vol. 294, no. 13, p. 1722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Burnham, J. Shults, S. E. Dubner, H. Sembhi, B. S. Zemel, and M. B. Leonard, “Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2518–2527, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. P. J. Hashkes and R. M. Laxer, “Medical treatment of juvenile idiopathic arthritis,” Journal of the American Medical Association, vol. 294, no. 13, pp. 1671–1684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Prockop, “Marrow stromal cells as stem cells for nonhematopoietic tissues,” Science, vol. 276, no. 5309, pp. 71–74, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Zhang, D. Khan, J. Delling, and E. Tobiasch, “Mechanisms underlying the osteo- and adipo-differentiation of human mesenchymal stem cells,” The Scientific World Journal, vol. 2012, Article ID 793823, 14 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. O. K. Lee, T. K. Kuo, W.-M. Chen, K.-D. Lee, S.-L. Hsieh, and T.-H. Chen, “Isolation of multipotent mesenchymal stem cells from umbilical cord blood,” Blood, vol. 103, no. 5, pp. 1669–1675, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Zippel, C. A. Limbach, N. Ratajski et al., “Purinergic receptors influence the differentiation of human mesenchymal stem cells,” Stem Cells and Development, vol. 21, no. 6, pp. 884–900, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. H. K. Salem and C. Thiemermann, “Mesenchymal stromal cells: current understanding and clinical status,” Stem Cells, vol. 28, no. 3, pp. 585–596, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. A. J. Nauta and W. E. Fibbe, “Immunomodulatory properties of mesenchymal stromal cells,” Blood, vol. 110, no. 10, pp. 3499–3506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Wang, L. Wang, X. Cong et al., “Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy,” Stem Cells and Development, vol. 22, no. 24, pp. 3192–3202, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. F. M. Van Der Heijde, M. Van't Hof, P. L. C. M. Van Riel, and L. B. A. Van De Putte, “Development of a disease activity score based on judgment in clinical practice by rheumatologists,” Journal of Rheumatology, vol. 20, no. 3, pp. 579–581, 1993. View at Google Scholar · View at Scopus
  12. Y. Xu, H. Meng, C. Li et al., “Umbilical cord-derived mesenchymal stem cells isolated by a novel explantation technique can differentiate into functional endothelial cells and promote revascularization,” Stem Cells and Development, vol. 19, no. 10, pp. 1511–1522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. C. William and J. R. Shiel, Eds., Juvenile Rheumatoid Arthritis, MedicineNet, 2012.
  15. A. Woerner, A. von Scheven-Gête, R. Cimaz, and M. Hofer, “Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations,” Expert Review of Clinical Immunology, vol. 11, no. 5, pp. 575–588, 2015. View at Publisher · View at Google Scholar
  16. W. Zhao, D. G. Phinney, D. Bonnet, M. Dominici, and M. Krampera, “Mesenchymal stem cell biodistribution, migration, and homing in vivo,” Stem Cells International, vol. 2014, Article ID 292109, 2 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Ullah, R. B. Subbarao, and G. J. Rho, “Human mesenchymal stem cells—current trends and future prospective,” Bioscience Reports, vol. 35, no. 2, Article ID e00191, 2015. View at Publisher · View at Google Scholar
  18. K. Nemeth, “Mesenchymal stem cell therapy for immune-modulation: the donor, the recipient, and the drugs in-between,” Experimental Dermatology, vol. 23, no. 9, pp. 625–628, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Song, L. Gao, H. Qiu et al., “Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant,” International Journal of Molecular Medicine, vol. 36, no. 1, pp. 139–149, 2015. View at Publisher · View at Google Scholar
  20. A. Del Fattore, R. Luciano, L. Pascucci et al., “Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes,” Cell Transplantation, 2015. View at Publisher · View at Google Scholar
  21. I. Perea-Gil, M. Monguió-Tortajada, C. Gálvez-Montón, A. Bayes-Genis, F. E. Borràs, and S. Roura, “Preclinical evaluation of the immunomodulatory properties of cardiac adipose tissue progenitor cells using umbilical cord blood mesenchymal stem cells: a direct comparative study,” BioMed Research International, vol. 2015, Article ID 439808, 9 pages, 2015. View at Publisher · View at Google Scholar
  22. S. Shawki, T. Gaafar, H. Erfan, E. E. Khateeb, A. E. Sheikhah, and R. E. Hawary, “Immunomodulatory effects of umbilical cord-derived mesenchymal stem cells,” Microbiology and Immunology, vol. 59, no. 6, pp. 348–356, 2015. View at Publisher · View at Google Scholar
  23. L.-L. Lu, Y.-J. Liu, S.-G. Yang et al., “Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials,” Haematologica, vol. 91, no. 8, pp. 1017–1026, 2006. View at Google Scholar · View at Scopus
  24. R. Atoui and R. C. J. Chiu, “Immune responses after mesenchymal stem cell implantation,” in Cellular Cardiomyoplasty, vol. 1036 of Methods in Molecular Biology, pp. 107–120, Humana Press, 2015. View at Publisher · View at Google Scholar
  25. K. A. T. de Carvalho, G. Steinhoff, and J. C. Chachques, “Mesenchymal stem cell therapy in nonhematopoietic diseases,” Stem Cells International, vol. 2015, Article ID 676903, 2 pages, 2015. View at Publisher · View at Google Scholar
  26. L. Sun, D. Wang, J. Liang et al., “Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 62, no. 8, pp. 2467–2475, 2010. View at Publisher · View at Google Scholar · View at Scopus